Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy

BACKGROUND: Bringing antibodies from pre-clinical studies to human trials requires humanization, but this process may alter properties that are crucial for efficacy. Since pathological tau protein is primarily intraneuronal in Alzheimer's disease, the most efficacious antibodies should work bot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Congdon, Erin E., Chukwu, Jessica E., Shamir, Dov B., Deng, Jingjing, Ujla, Devyani, Sait, Hameetha B.R., Neubert, Thomas A., Kong, Xiang-Peng, Sigurdsson, Einar M.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Research paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492224/
https://ncbi.nlm.nih.gov/pubmed/30910484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.03.033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados